Anizatrectinib
Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al[1].
Product Specifications
CAS Number
1824664-89-2
Product Name Alternative
HTrkA-IN-1
UNSPSC
12352005
Target
Trk Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/anizatrectinib.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=C(C)C(C2=CN=C(C)N=C2)=NN1C3=CC=CC=C3)N[C@@H]4CN(CCOC)C[C@H]4C5=CC=CC(F)=C5
Molecular Formula
C29H32FN7O2
Molecular Weight
529.61
References & Citations
[1]Shelley Allen, et al. 1- ((3s,4r) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2-methylpyrimidin-5-yl) -1-phenyl-1h-pyrazol-5-yl) urea as a trka kinase inhibitor. Patent WO2015175788A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TrkA
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
